7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, investing in o...
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| 13.37 | |
| 13.61 | |
| - | |
| 13.71 | |
| 13.13 | |
| 10.29-20.23 | |
| 803 M | |
| 60 326 K | |
| 248 K | |
| -0.78 | |
| 1.164 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, investing in o...
Keith Cummings, the CFO of Pliant Therapeutics Inc, sold 9,781 shares of the company on January 17, 2024, according to a recent SEC filing. The transaction was executed at an average price of $17.23 p...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: